BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 18305386)

  • 1. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline.
    Noordzij M; Korevaar JC; Dekker FW; Boeschoten EW; Bos WJ; Krediet RT; Bossuyt PM; Geskus RB;
    Blood Purif; 2008; 26(3):231-7. PubMed ID: 18305386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.
    Noordzij M; Korevaar JC; Bos WJ; Boeschoten EW; Dekker FW; Bossuyt PM; Krediet RT
    Nephrol Dial Transplant; 2006 Sep; 21(9):2513-20. PubMed ID: 16799173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.
    Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT;
    Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients.
    Phelan PJ; O'Kelly P; Walshe JJ; Conlon PJ
    Ren Fail; 2008; 30(4):423-9. PubMed ID: 18569917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
    Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
    J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disordered mineral metabolism is not a risk factor for loss of residual renal function in dialysis patients.
    Noordzij M; Voormolen NM; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT; Korevaar JC;
    Nephrol Dial Transplant; 2009 May; 24(5):1580-7. PubMed ID: 19155531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risk factors associated with survival in patients in a peritoneal dialysis program].
    Sancho A; Pérez Ruixo JJ; Górriz JL; Miguel A; García Ramón R; Avila A
    Nefrologia; 2001; 21(2):160-6. PubMed ID: 11464649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uncorrected and Albumin-Corrected Calcium, Phosphorus, and Mortality in Patients Undergoing Maintenance Dialysis.
    Rivara MB; Ravel V; Kalantar-Zadeh K; Streja E; Lau WL; Nissenson AR; Kestenbaum B; de Boer IH; Himmelfarb J; Mehrotra R
    J Am Soc Nephrol; 2015 Jul; 26(7):1671-81. PubMed ID: 25613037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
    Naves-Díaz M; Passlick-Deetjen J; Guinsburg A; Marelli C; Fernández-Martín JL; Rodríguez-Puyol D; Cannata-Andía JB
    Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition.
    de Mutsert R; Grootendorst DC; Indemans F; Boeschoten EW; Krediet RT; Dekker FW;
    J Ren Nutr; 2009 Mar; 19(2):127-35. PubMed ID: 19218039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
    Danese MD; Kim J; Doan QV; Dylan M; Griffiths R; Chertow GM
    Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program.
    Wazny LD; Raymond CB; Lesperance EM; Bernstein KN
    CANNT J; 2008; 18(2):36-41, 44-50; quiz 42-3, 51-2. PubMed ID: 18669010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which targets in clinical practice guidelines are associated with improved survival in a large dialysis organization?
    Tentori F; Hunt WC; Rohrscheib M; Zhu M; Stidley CA; Servilla K; Miskulin D; Meyer KB; Bedrick EJ; Johnson HK; Zager PG
    J Am Soc Nephrol; 2007 Aug; 18(8):2377-84. PubMed ID: 17634440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Kimata N; Akiba T; Pisoni RL; Albert JM; Satayathum S; Cruz JM; Akizawa T; Andreucci VE; Young EW; Port FK
    Nephrol Dial Transplant; 2005 May; 20(5):927-35. PubMed ID: 15728270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between a self-rated health question and mortality in young and old dialysis patients: a cohort study.
    Thong MS; Kaptein AA; Benyamini Y; Krediet RT; Boeschoten EW; Dekker FW;
    Am J Kidney Dis; 2008 Jul; 52(1):111-7. PubMed ID: 18511166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients.
    Noordzij M; Boeschoten EW; Bos WJ; Dekker FW; Bossuyt PM; Krediet RT; Korevaar JC;
    Nephrol Dial Transplant; 2007 Oct; 22(10):2944-9. PubMed ID: 17597087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CA-P control in haemodialysis and K/DOQI guidelines].
    Rivera F; Sánchez de la Nieta MD; Echarri R; Anaya S; Carreño A; Vozmediano MC; Alcaide MP
    Nefrologia; 2006; 26(3):351-7. PubMed ID: 16892824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.